Condition
HOCM, Hypertrophic Obstructive Cardiomyopathy
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Unknown2
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04349072Phase 3CompletedPrimary
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
NCT04265040Recruiting
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
NCT04230551Not ApplicableUnknownPrimary
Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction
NCT01875016Not ApplicableUnknownPrimary
CRyo-Ablation to Treat Patients With HOCM.
Showing all 4 trials